Literature DB >> 28793143

Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy.

Franco Cecchi1, Maria Iascone2, Niccolò Maurizi3, Laura Pezzoli2, Irene Binaco1, Elena Biagini4, Maria Laura Fibbi5, Iacopo Olivotto3, Federico Pieruzzi6, Ana Fruntelata7, Lucian Dorobantu7, Claudio Rapezzi4, Paolo Ferrazzi1.   

Abstract

Importance: Diagnostic screening for Anderson-Fabry cardiomyopathy (AFC) is performed in the presence of specific clinical red flags in patients with hypertrophic cardiomyopathy (HCM) older than 25 years. However, left ventricular outflow tract obstruction (LVOTO) has been traditionally considered an exclusion criteria for AFC. Objective: To examine a series of patients diagnosed with HCM and severe basal LVOTO undergoing myectomy in whom the diagnosis of AFC was suspected by the cardiac surgeon intraoperatively and confirmed by histological and genetic examinations. Design, Setting, and Participants: This retrospective analysis of patients undergoing surgical septal reduction strategies was conducted in 3 European tertiary referral centers for HCM from July 2013 to December 2016. Patients with a clinical diagnosis of obstructive HCM referred for surgical management of LVOTO were observed for at least 18 months after the procedure (mean [SD] follow-up, 33 [14] months). Main Outcomes and Measures: Etiology of patients with HCM who underwent surgical myectomy.
Results: From 2013, 235 consecutive patients with a clinical diagnosis of HCM underwent septal myectomy. The cardiac surgeon suspected a storage disease in 3 patients (1.3%) while inspecting their heart samples extracted from myectomy. The mean (SD) age at diagnosis for these 3 patients was 42 (4) years; all were male. None of the 3 patients presented with extracardiac features suggestive of AFC. All patients showed asymmetrical left ventricular hypertrophy, with maximal left ventricular thickness in the basal septum (19-31 mm), severe basal LVOTO (70-120 mm Hg), and left atrial dilatation (44-57 mm). Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic resonance at the right ventricle insertion site. The mean (SD) age at surgical procedure was 63 (5) years. On tactile sensation, the surgeon felt a spongy consistency of the surgical samples, different from the usual stony-elastic consistency typical of classic HCM, and this prompted histological examinations. Histology showed evidence of intracellular storage, and genetic analysis confirmed a GLA A gene mutation (p.Asn215Ser) in all 3 patients. Conclusions and Relevance: Screening for AFC should be performed even in the absence of red flags in patients with HCM older than 25 years.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28793143      PMCID: PMC5815007          DOI: 10.1001/jamacardio.2017.2353

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  15 in total

1.  Fabry's disease with LVOT obstruction: diagnosis and management.

Authors:  Jacob R Blount; James K Wu; Matthew W Martinez
Journal:  J Card Surg       Date:  2013-09-02       Impact factor: 1.620

2.  Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease.

Authors:  Margherita Calcagnino; Constantinos O'Mahony; Caroline Coats; Montserrat Cardona; Alfredo Garcia; Kalajarasi Janagarajan; Atul Mehta; Derralynn Hughes; Elaine Murphy; Robin Lachmann; Perry M Elliott
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

3.  Fabry disease with resting outflow obstruction masquerading as hypertrophic cardiomyopathy.

Authors:  Jeffrey B Geske; Hayan Jouni; Marie C Aubry; Bernard J Gersh
Journal:  J Am Coll Cardiol       Date:  2014-03-13       Impact factor: 24.094

4.  Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics.

Authors:  Valentina Favalli; Eliana Disabella; Mariadelfina Molinaro; Marilena Tagliani; Anna Scarabotto; Alessandra Serio; Maurizia Grasso; Nupoor Narula; Carmela Giorgianni; Clelia Caspani; Monica Concardi; Manuela Agozzino; Calogero Giordano; Alexandra Smirnova; Takahide Kodama; Lorenzo Giuliani; Elena Antoniazzi; Riccardo G Borroni; Camilla Vassallo; Filippo Mangione; Laura Scelsi; Stefano Ghio; Carlo Pellegrini; Marialuisa Zedde; Laura Fancellu; GianPietro Sechi; Antonello Ganau; Stefania Piga; Annarita Colucci; Daniela Concolino; Maria Teresa Di Mascio; Danilo Toni; Marina Diomedi; Claudio Rapezzi; Elena Biagini; Massimiliano Marini; Maurizia Rasura; Maurizio Melis; Antonia Nucera; Donata Guidetti; Michelangelo Mancuso; Umberto Scoditti; Pamela Cassini; Jagat Narula; Luigi Tavazzi; Eloisa Arbustini
Journal:  J Am Coll Cardiol       Date:  2016-09-06       Impact factor: 24.094

Review 5.  Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.

Authors:  B E Smid; L van der Tol; F Cecchi; P M Elliott; D A Hughes; G E Linthorst; J Timmermans; F Weidemann; M L West; M Biegstraaten; R H Lekanne Deprez; S Florquin; P G Postema; B Tomberli; A C van der Wal; M A van den Bergh Weerman; C E Hollak
Journal:  Int J Cardiol       Date:  2014-09-20       Impact factor: 4.164

6.  Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey.

Authors:  Perry Elliott; Robert Baker; Ferdinando Pasquale; Giovanni Quarta; Hatim Ebrahim; Atul B Mehta; Derralynn A Hughes
Journal:  Heart       Date:  2011-09-02       Impact factor: 5.994

7.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

Authors:  Ales Linhart; Christoph Kampmann; José L Zamorano; Gere Sunder-Plassmann; Michael Beck; Atul Mehta; Perry M Elliott
Journal:  Eur Heart J       Date:  2007-05-05       Impact factor: 29.983

8.  Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases.

Authors:  Claudio Rapezzi; Eloisa Arbustini; Alida L P Caforio; Philippe Charron; Juan Gimeno-Blanes; Tiina Heliö; Ales Linhart; Jens Mogensen; Yigal Pinto; Arsen Ristic; Hubert Seggewiss; Gianfranco Sinagra; Luigi Tavazzi; Perry M Elliott
Journal:  Eur Heart J       Date:  2012-12-04       Impact factor: 29.983

9.  Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy.

Authors:  Paolo Ferrazzi; Paolo Spirito; Attilio Iacovoni; Alice Calabrese; Katrin Migliorati; Caterina Simon; Samuele Pentiricci; Daniele Poggio; Massimiliano Grillo; Pietro Amigoni; Maria Iascone; Andrea Mortara; Barry J Maron; Michele Senni; Paolo Bruzzi
Journal:  J Am Coll Cardiol       Date:  2015-10-13       Impact factor: 24.094

10.  A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy.

Authors:  Attilio Iacovoni; Paolo Spirito; Caterina Simon; Maria Iascone; Giovanni Di Dedda; Paolo De Filippo; Samuele Pentiricci; Luca Boni; Michele Senni; Antonello Gavazzi; Paolo Ferrazzi
Journal:  Eur Heart J       Date:  2012-04-20       Impact factor: 29.983

View more
  5 in total

1.  Importance of Echocardiography and Clinical "Red Flags" in Guiding Genetic Screening for Fabry Disease.

Authors:  Rodolfo Citro; Costantina Prota; Donatella Ferraioli; Giuseppe Iuliano; Michele Bellino; Ilaria Radano; Angelo Silverio; Serena Migliarino; Maria Vincenza Polito; Artemisia Ruggiero; Rosa Napoletano; Vincenzo Bellizzi; Michele Ciccarelli; Gennaro Galasso; Carmine Vecchione
Journal:  Front Cardiovasc Med       Date:  2022-04-25

2.  Yield of Rare Variants Detected by Targeted Next-Generation Sequencing in a Cohort of Romanian Index Patients with Hypertrophic Cardiomyopathy.

Authors:  Miruna Mihaela Micheu; Nicoleta-Monica Popa-Fotea; Nicoleta Oprescu; Stefan Bogdan; Monica Dan; Alexandru Deaconu; Lucian Dorobantu; Oana Gheorghe-Fronea; Maria Greavu; Corneliu Iorgulescu; Alexandru Scafa-Udriste; Razvan Ticulescu; Radu Gabriel Vatasescu; Maria Dorobanțu
Journal:  Diagnostics (Basel)       Date:  2020-12-07

3.  High Prevalence of Late-Onset Fabry Cardiomyopathy in a Cohort of 499 Non-Selective Patients with Left Ventricular Hypertrophy: The Asian Fabry Cardiomyopathy High-Risk Screening Study (ASIAN-FAME).

Authors:  Yiting Fan; Tsz-Ngai Chan; Josie T Y Chow; Kevin K H Kam; Wai-Kin Chi; Joseph Y S Chan; Erik Fung; Mabel M P Tong; Jeffery K T Wong; Paul C L Choi; David K H Chan; Bun Sheng; Alex Pui-Wai Lee
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

4.  Impact of cardiac magnetic resonance on the diagnosis of hypertrophic cardiomyopathy - a 10-year experience with over 1000 patients.

Authors:  Mateusz Śpiewak; Mariusz Kłopotowski; Natalia Ojrzyńska; Joanna Petryka-Mazurkiewicz; Barbara Miłosz-Wieczorek; Łukasz Mazurkiewicz; Jacek Grzybowski; Zofia Bilińska; Adam Witkowski; Magdalena Marczak
Journal:  Eur Radiol       Date:  2020-09-02       Impact factor: 5.315

5.  Evidence of evolution towards left midventricular obstruction in severe Anderson-Fabry cardiomyopathy.

Authors:  Francesca Graziani; Rosa Lillo; Elena Panaioli; Gionata Spagnoletti; Maurizio Pieroni; Paolo Ferrazzi; Antonia Camporeale; Elena Verrecchia; Ludovico Luca Sicignano; Raffaele Manna; Filippo Crea
Journal:  ESC Heart Fail       Date:  2020-11-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.